Trial Review

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616000833460
Ethics application status
Approved
Date submitted
16/06/2016
Date registered
24/06/2016
Date last updated
24/02/2020
Date data sharing statement initially provided
14/01/2019
Date results provided
14/01/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Real life assessment of SGLT2 inhibitors for type 2 diabetes
Scientific title
Efficacy of SGLT2 inhibitors in a tertiary hospital type 2 diabetes clinic
Secondary ID [1] 289480 0
Nil known
Universal Trial Number (UTN)
U1111-1184-3691
Trial acronym
RMH-SGLT2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Type 2 diabetes 299165 0
Condition category
Condition code
Metabolic and Endocrine 299180 299180 0 0
Diabetes

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Oral SGLT2 inhibitor, including dapagliflozin, empagliflozin and canagliflozin. The dose and frequency will be determined by the treating clinician as per standard care and will not be defined as part of this study. Each patient will be followed with blood tests and questionnaires at 3 and 6 months after starting SGLT2 inhibitor therapy.
Intervention code [1] 295066 0
Not applicable
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 298661 0
HbA1c by clinically accredited laboratory using EDTA blood sample
Timepoint [1] 298661 0
3 months after starting SGLT2 inhibitor therapy
Secondary outcome [1] 324874 0
HbA1c by clinically accredited laboratory using EDTA blood sample
Timepoint [1] 324874 0
3 and 6 months after starting SGTLTI
Secondary outcome [2] 324896 0
Weight, measured by digital scales
Timepoint [2] 324896 0
3 and 6 months after starting SGLT2I
Secondary outcome [3] 324897 0
Blood pressure by automated sphygmomanometer
Timepoint [3] 324897 0
3 and 6 months after starting SGLT2I
Secondary outcome [4] 324898 0
Blood ketones measured by ambulatory home monitor (Abbott Freestyle Neo)
Timepoint [4] 324898 0
3 and 6 months after starting SGLT2I
Secondary outcome [5] 324899 0
Urine fractional excretion of glucose and electrolytes (change from baseline)
Timepoint [5] 324899 0
3 and 6 months after starting SGLT2I
Secondary outcome [6] 324900 0
Urine albumin/creatinine ratio (change from baseline)
Timepoint [6] 324900 0
3 and 6 months after starting SGLT2I
Secondary outcome [7] 324901 0
Change in number and dose of glucose-lowering and blood pressure-lowering medications from baseline. These data will be obtained through participant interview.
Timepoint [7] 324901 0
3 and 6 months after starting SGLT2I
Secondary outcome [8] 324902 0
Lipid profile, assessed by an accredited laboratory using a serum sample
Timepoint [8] 324902 0
3 and 6 months after starting SGLT2I
Secondary outcome [9] 324903 0
Quality of life, measured using the SF-36 survey
Timepoint [9] 324903 0
3 and 6 months after starting SGLT2I
Secondary outcome [10] 324904 0
Adverse events of interest (genitourinary infection, fracture and hypovolaemia) will be sought during clinician assessment at 3 and 6 months
Timepoint [10] 324904 0
3 and 6 months after starting SGLT2I
Secondary outcome [11] 324982 0
Health utility using the EQ-5D survey
Timepoint [11] 324982 0
3 and 6 months

Eligibility
Key inclusion criteria
Type 2 diabetes according to ADA criteria
No planned changes to glucose-lowering or blood pressure-lowering therapy
Due to commence SGLT2 inhibitor therapy
Willing to comply with therapy, tests and clinical follow-up
Deemed unlikely to require adjustment of blood pressure- or lipid-lowering medication over the next 6 months
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Unable to provide informed consent
Use of SGLT2 inhibitor in previous fortnight
Contra-indication to SGLT2 inhibitor therapy, including stage 4 or 5 chronic kidney disease (eGFR<30) and history of genitourinary infection
Presence of a comorbidity that, in the investigators’ opinion, would impair compliance with SGLT2 inhibitor therapy or the study protocol
Pregnancy or desire for pregnancy within the next year
Urinary frequency that may prevent abstinence from urination for the 5-hour period before clinic visits

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis
Analyses will be performed using GraphPad and R software. Grouped and categorical data will be compared by t-test and Fisher’s exact test respectively, and correlations will be performed using the method of Pearson. Multiple regression analyses will be performed using the lm function in R.
To determine if SGLT2 inhibitor therapy is associated with a mean+/-SD reduction in HbA1c of 0.5+/-1.0%, 40 participants need to complete the study to achieve >85% statistical power (alpha=0.05, two-tail). We expect up to 10 patients will withdraw from the study. The final sample size will therefore be 50 participants.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/07/2016
Actual
1/09/2016
Date of last participant enrolment
Anticipated
30/06/2017
Actual
30/11/2017
Date of last data collection
Anticipated
Actual
4/06/2018
Sample size
Target
50
Accrual to date
Final
53
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 5994 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment postcode(s) [1] 13419 0
3050 - Royal Melbourne Hospital

Funding & Sponsors
Funding source category [1] 293841 0
Hospital
Name [1] 293841 0
Royal Melbourne Hospital Diabetes and Endocrinology
Country [1] 293841 0
Australia
Primary sponsor type
Individual
Name
John Wentworth
Address
RMH Diabetes and Endocrinology
Grattan St
Parkville, Vic 3050
Country
Australia
Secondary sponsor category [1] 292678 0
None
Name [1] 292678 0
Address [1] 292678 0
Country [1] 292678 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 295268 0
Melbourne Health HREC
Ethics committee address [1] 295268 0
Ethics committee country [1] 295268 0
Australia
Date submitted for ethics approval [1] 295268 0
08/04/2016
Approval date [1] 295268 0
06/06/2016
Ethics approval number [1] 295268 0
2016.009

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 66730 0
A/Prof John Wentworth
Address 66730 0
RMH Diabetes and Endocrinology Grattan St Parkville, Vic 3050
Country 66730 0
Australia
Phone 66730 0
+61422992891
Fax 66730 0
+61393470852
Email 66730 0
[email protected]
Contact person for public queries
Name 66731 0
John Wentworth
Address 66731 0
RMH Diabetes and Endocrinology Grattan St Parkville, Vic 3050
Country 66731 0
Australia
Phone 66731 0
+61422992891
Fax 66731 0
+61393470852
Email 66731 0
[email protected]
Contact person for scientific queries
Name 66732 0
John Wentworth
Address 66732 0
RMH Diabetes and Endocrinology Grattan St Parkville, Vic 3050
Country 66732 0
Australia
Phone 66732 0
+61422992891
Fax 66732 0
+61393470852
Email 66732 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Any researcher who applies to A/Prof John Wentworth to obtain it.

Conditions for requesting access:
• -

What individual participant data might be shared?
• Clinical and biochemical data

What types of analyses could be done with individual participant data?
• Any approved analyses

When can requests for individual participant data be made (start and end dates)?
From:
31/12/2019 indefinitely

To:
-

Where can requests to access individual participant data be made, or data be obtained directly?
• Email of de-identified excel file

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseFactors that predict glycaemic response to sodium-glucose linked transporter (SGLT) inhibitors.2021https://dx.doi.org/10.1111/imj.14805
N.B. These documents automatically identified may not have been verified by the study sponsor.